Which has stronger earnings and valuation, LYEL or MGTX?

MeiraGTx has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lyell Immunopharma $40K 8,771.00 -$274.45M -$12.83 N/A MeiraGTx $81.39M 16.48 -$114.20M $0.71 19.68

Does the media favor LYEL or MGTX?

In the previous week, MeiraGTx had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for MeiraGTx and 1 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.67 beat MeiraGTx's score of 1.41 indicating that Lyell Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MeiraGTx 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LYEL or CGEM?

In the previous week, Cullinan Therapeutics had 3 more articles in the media than Lyell Immunopharma. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 1 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.67 beat Cullinan Therapeutics' score of 1.18 indicating that Lyell Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cullinan Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LYEL or OMER more profitable?

Omeros has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Lyell Immunopharma's return on equity of -91.62% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Lyell Immunopharma -920,285.25% -91.62% -70.50% Omeros N/A -164.92% 69.41%

Does the media favor LYEL or OMER?

In the previous week, Omeros had 14 more articles in the media than Lyell Immunopharma. MarketBeat recorded 15 mentions for Omeros and 1 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.67 beat Omeros' score of 0.69 indicating that Lyell Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Omeros 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AKTS or LYEL?

In the previous week, Aktis Oncology had 4 more articles in the media than Lyell Immunopharma. MarketBeat recorded 5 mentions for Aktis Oncology and 1 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.67 beat Aktis Oncology's score of 1.59 indicating that Lyell Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lyell Immunopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor LYEL or ORIC?

In the previous week, Oric Pharmaceuticals had 6 more articles in the media than Lyell Immunopharma. MarketBeat recorded 7 mentions for Oric Pharmaceuticals and 1 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.67 beat Oric Pharmaceuticals' score of 0.95 indicating that Lyell Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Oric Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lyell Immunopharma (LYEL) Competitors

$14.32 -0.63 (-4.21%)

As of 04:00 PM Eastern

Compare

LYEL vs. MGTX, CGEM, OMER, AKTS, and ORIC

Should you buy Lyell Immunopharma stock or one of its competitors? Lyell Immunopharma's main competitors and comparable companies include MeiraGTx (MGTX), Cullinan Therapeutics (CGEM), Omeros (OMER), Aktis Oncology (AKTS), and Oric Pharmaceuticals (ORIC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lyell Immunopharma compare to MeiraGTx?

Lyell Immunopharma (NASDAQ:LYEL) and MeiraGTx (NASDAQ:MGTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, MeiraGTx had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for MeiraGTx and 1 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.67 beat MeiraGTx's score of 1.41 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MeiraGTx	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MeiraGTx has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	8,771.00	-$274.45M	-$12.83	N/A
MeiraGTx	$81.39M	16.48	-$114.20M	$0.71	19.68

Lyell Immunopharma has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 7.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MeiraGTx has a net margin of 19.87% compared to Lyell Immunopharma's net margin of -920,285.25%. MeiraGTx's return on equity of 283.85% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%
MeiraGTx	19.87%	283.85%	29.39%

Lyell Immunopharma presently has a consensus price target of $40.86, suggesting a potential upside of 185.32%. MeiraGTx has a consensus price target of $26.17, suggesting a potential upside of 87.31%. Given Lyell Immunopharma's higher probable upside, research analysts clearly believe Lyell Immunopharma is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
MeiraGTx	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

MeiraGTx beats Lyell Immunopharma on 13 of the 17 factors compared between the two stocks.

How does Lyell Immunopharma compare to Cullinan Therapeutics?

Lyell Immunopharma (NASDAQ:LYEL) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lyell Immunopharma has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

Cullinan Therapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Cullinan Therapeutics' return on equity of -52.89% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

In the previous week, Cullinan Therapeutics had 3 more articles in the media than Lyell Immunopharma. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 1 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.67 beat Cullinan Therapeutics' score of 1.18 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cullinan Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lyell Immunopharma presently has a consensus price target of $40.86, suggesting a potential upside of 185.32%. Cullinan Therapeutics has a consensus price target of $32.86, suggesting a potential upside of 48.27%. Given Lyell Immunopharma's higher probable upside, research analysts plainly believe Lyell Immunopharma is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Cullinan Therapeutics has lower revenue, but higher earnings than Lyell Immunopharma. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	8,771.00	-$274.45M	-$12.83	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

Summary

Cullinan Therapeutics beats Lyell Immunopharma on 9 of the 13 factors compared between the two stocks.

How does Lyell Immunopharma compare to Omeros?

Lyell Immunopharma (NASDAQ:LYEL) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Omeros has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Lyell Immunopharma's return on equity of -91.62% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%
Omeros	N/A	-164.92%	69.41%

Lyell Immunopharma has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market. Comparatively, Omeros has a beta of 2.6, indicating that its share price is 160% more volatile than the broader market.

66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 6.2% of Lyell Immunopharma shares are owned by insiders. Comparatively, 10.5% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Omeros has lower revenue, but higher earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	8,771.00	-$274.45M	-$12.83	N/A
Omeros	N/A	N/A	-$3.35M	$1.28	14.93

In the previous week, Omeros had 14 more articles in the media than Lyell Immunopharma. MarketBeat recorded 15 mentions for Omeros and 1 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.67 beat Omeros' score of 0.69 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Omeros	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lyell Immunopharma presently has a consensus price target of $40.86, suggesting a potential upside of 185.32%. Omeros has a consensus price target of $38.00, suggesting a potential upside of 98.85%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Lyell Immunopharma is more favorable than Omeros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Omeros beats Lyell Immunopharma on 8 of the 15 factors compared between the two stocks.

How does Lyell Immunopharma compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

In the previous week, Aktis Oncology had 4 more articles in the media than Lyell Immunopharma. MarketBeat recorded 5 mentions for Aktis Oncology and 1 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.67 beat Aktis Oncology's score of 1.59 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lyell Immunopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Aktis Oncology currently has a consensus price target of $35.00, indicating a potential upside of 31.33%. Lyell Immunopharma has a consensus price target of $40.86, indicating a potential upside of 185.32%. Given Lyell Immunopharma's higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Aktis Oncology has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Aktis Oncology's return on equity of 0.00% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aktis Oncology has higher revenue and earnings than Lyell Immunopharma. Aktis Oncology is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	220.38	-$63.73M	-$0.82	N/A
Lyell Immunopharma	$40K	8,771.00	-$274.45M	-$12.83	N/A

Summary

Aktis Oncology beats Lyell Immunopharma on 9 of the 15 factors compared between the two stocks.

How does Lyell Immunopharma compare to Oric Pharmaceuticals?

Lyell Immunopharma (NASDAQ:LYEL) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Lyell Immunopharma presently has a consensus price target of $40.86, indicating a potential upside of 185.32%. Oric Pharmaceuticals has a consensus price target of $19.45, indicating a potential upside of 52.70%. Given Lyell Immunopharma's higher possible upside, equities research analysts clearly believe Lyell Immunopharma is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Oric Pharmaceuticals had 6 more articles in the media than Lyell Immunopharma. MarketBeat recorded 7 mentions for Oric Pharmaceuticals and 1 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.67 beat Oric Pharmaceuticals' score of 0.95 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Oric Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lyell Immunopharma has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

Oric Pharmaceuticals has lower revenue, but higher earnings than Lyell Immunopharma. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	8,771.00	-$274.45M	-$12.83	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

Oric Pharmaceuticals has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Oric Pharmaceuticals' return on equity of -35.35% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Oric Pharmaceuticals beats Lyell Immunopharma on 10 of the 16 factors compared between the two stocks.

Get Lyell Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LYEL vs. The Competition

Export

Metric	Lyell Immunopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$366.46M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-1.12	12.66	273.28	25.38
Price / Sales	8,771.00	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	1.50	16.29	12.89	6.14
Net Income	-$274.45M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-1.98%	-1.37%	-0.33%	-1.47%
1 Month Performance	11.27%	11.07%	6.51%	2.47%
1 Year Performance	25.28%	53.71%	25.19%	15.84%

Lyell Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LYEL Lyell Immunopharma	3.4488 of 5 stars	$14.32 -4.2%	$40.86 +185.3%	+31.0%	$366.46M	$40K	N/A	270	Positive News
MGTX MeiraGTx	4.132 of 5 stars	$14.92 +0.6%	$26.17 +75.4%	+92.6%	$1.42B	$81.39M	21.01	300
CGEM Cullinan Therapeutics	2.9235 of 5 stars	$22.95 +5.2%	$32.86 +43.2%	+198.1%	$1.40B	N/A	N/A	30	Positive News
OMER Omeros	4.0554 of 5 stars	$19.28 -0.2%	$38.00 +97.1%	+339.6%	$1.40B	N/A	15.06	210	Insider Trade
AKTS Aktis Oncology	2.9862 of 5 stars	$26.69 +2.7%	$35.00 +31.1%	N/A	$1.40B	$6.50M	N/A	76	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LYEL) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lyell Immunopharma (LYEL) Competitors

LYEL vs. MGTX, CGEM, OMER, AKTS, and ORIC

How does Lyell Immunopharma compare to MeiraGTx?

Summary

How does Lyell Immunopharma compare to Cullinan Therapeutics?

Summary

How does Lyell Immunopharma compare to Omeros?

Summary

How does Lyell Immunopharma compare to Aktis Oncology?

Summary

How does Lyell Immunopharma compare to Oric Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lyell Immunopharma (LYEL) Competitors

LYEL vs. MGTX, CGEM, OMER, AKTS, and ORIC

How does Lyell Immunopharma compare to MeiraGTx?

Does the media favor LYEL or MGTX?

Which has stronger earnings and valuation, LYEL or MGTX?

Which has more volatility & risk, LYEL or MGTX?

Do institutionals & insiders have more ownership in LYEL or MGTX?

Is LYEL or MGTX more profitable?

Do analysts rate LYEL or MGTX?

Summary

How does Lyell Immunopharma compare to Cullinan Therapeutics?

Do institutionals & insiders have more ownership in LYEL or CGEM?

Which has more risk and volatility, LYEL or CGEM?

Is LYEL or CGEM more profitable?

Does the media favor LYEL or CGEM?

Do analysts prefer LYEL or CGEM?

Which has better earnings and valuation, LYEL or CGEM?

Summary

How does Lyell Immunopharma compare to Omeros?

Is LYEL or OMER more profitable?

Which has more volatility and risk, LYEL or OMER?

Do insiders and institutionals have more ownership in LYEL or OMER?

Which has preferable earnings and valuation, LYEL or OMER?

Does the media favor LYEL or OMER?

Do analysts recommend LYEL or OMER?

Summary

How does Lyell Immunopharma compare to Aktis Oncology?

Does the media prefer AKTS or LYEL?

Do analysts recommend AKTS or LYEL?

Is AKTS or LYEL more profitable?

Do institutionals & insiders have more ownership in AKTS or LYEL?

Which has better earnings and valuation, AKTS or LYEL?

Summary

How does Lyell Immunopharma compare to Oric Pharmaceuticals?

Do analysts recommend LYEL or ORIC?

Does the media favor LYEL or ORIC?

Which has more risk and volatility, LYEL or ORIC?

Which has stronger valuation and earnings, LYEL or ORIC?

Is LYEL or ORIC more profitable?

Do institutionals and insiders have more ownership in LYEL or ORIC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools